GleamWall
中文EN

RVPH REVIVA PHARMACEUTICALS HOLDINGS, INC.

Pharmaceutical Preparations · OTC · SEC CIK 1742927 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY50.3%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-128.3%
ROA-68.8%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets29.5%
Debt / equity0.00x
Current ratio3.39x
Interest coverage-2,310.59x

Cash quality & payout

Operating cash flow / net income1.23x
Accruals ratio15.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$1.20M$1.39M$1.44M$1.74M$2.13M$3.72M$4.11M$4.68M
SG&A expense$1.23M$1.22M$1.84M$1.82M$1.90M$2.35M$2.42M$1.60M
Operating income-$2.43M-$2.62M-$3.27M-$3.56M-$4.03M-$6.07M-$6.54M-$6.28M
Interest expense$1,174$2,935$6,653-$5,620$2,605$4,797$11,620$4,711
Pretax income-$2.30M-$2.45M-$3.19M-$3.36M-$4.01M-$6.05M-$6.43M-$6.25M
Income tax$1,934$2,632$3,346$2,882$2,840$7,954$5,213$4,733
Net income-$2.30M-$2.45M-$3.20M-$3.37M-$4.01M-$6.05M-$6.43M-$6.26M
EPS (basic)-0.17-0.19-0.46—-1.09-2.40-2.61—
EPS (diluted)————————
Balance sheet
Cash & equivalents$17.46M$19.89M$22.19M$14.44M$13.18M$10.36M$5.29M$13.48M
Current assets$18.56M$21.14M$23.56M$15.10M$13.51M$10.82M$6.26M$14.68M
Total assets$18.56M$21.14M$23.56M$15.92M$14.33M$11.63M$7.08M$15.50M
Current liabilities$5.48M$5.93M$6.12M$7.28M$9.74M$12.08M$11.51M$14.60M
Short-term debt$44,388$144,093$231,274$406,875$0$113,246$224,300$458,154
Total liabilities$5.48M$5.93M$6.12M$7.28M$9.78M$12.09M$11.54M$14.69M
Shareholders' equity$13.08M$15.21M$17.44M$8.65M$4.55M-$459,147-$4.46M$812,572
Shares outstanding13.11M13.11M12.81M5.87M96.34M68.00M46.74M2.36M
Cash flow statement
Operating cash flow-$2.18M-$2.12M-$3.80M-$5.80M-$5.59M-$5.01M-$8.19M-$9.10M
Financing cash flow-$247,189-$184,869$11.55M$7.05M$8.41M$10.09M$7,271$17.02M
Stock-based compensation$171,021$214,565$584,439$455,084$458,379$395,277$919,119$554,216

Free plan shows the latest 8 periods; Pro shows all 37 🔒

· This company does not report gross profit in XBRL.

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.